Pfizer's Zoloft going strong

Another ruling went in favor of the defendant, drug manufacturer Pfizer, for its antidepressant drug Zoloft by a panel of the 3rd U.S. Circuit Court of Appeals in Philadelphia, when they ruled to uphold the April 2016 dismissal of 300 Zoloft cases on the grounds that the testimony given by the Plaintiff's end wasn't backed by a thorough scientific link. The order was passed earlier by U.S. District Judge Cynthia Rufe in Philadelphia. The company now confidently claims that "extensive science" supports the safety and efficacy of Zoloft and is running high on their 2016 sales that had crossed $300 million. Zoloft belongs to a group of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). MDL 2342: Zoloft (Sertraline Hydrochloride) Products Liability Litigation was set up in 2012 wherein the manufacturer faces allegations that Zoloft causes cardiac birth defects in children when taken by women during early pregnancy.

Key Notes

On a closing note, FDA has also reported that this year the number of adverse events reported for the Morcellator related cancer incidents have reduced significantly; whereas, the number of Essure implants related adverse events reports have gone up. Two cases have also been shortlisted by the US District Court for the Northern District of Illinois in the Testosterone Replacement Therapy Product Liability Litigation, MDL 2545, against Eli Lilly and other drug companies alleging that the TRT therapy leads to the development of cardiovascular and other related conditions. On the other hand, drug maker AbbVie, also faced the first bellwether trial in a federal court in Chicago earlier this June for its low-t product, Androgel, accusing the company for its aggressive marketing strategies leading to thousands of men and their doctors to believe that they had low-t levels, which was actually a normal sign of aging.

The unpredictable rise and fall in the litigations subject to legal announcements keep the lawyers and plaintiffs on toes, and they need a strong will and melancholic temperament to keep going and succeeding.With the advent of summer, we are in the second half of 2017. Now is an ideal time to review and define what the future holds.

We are social:



Neural IT has successfully implemented HIPAA for securing Health records....

ISO 27001 Certification

Neural IT has successfully passed the ISMS re-certification audit and is now ISO 27001:2013 certi...


NSIC-CRISIL has assigned a "SE 2A" rating to Neural IT, indicating a company with High Performanc...



CAALA - "Neural IT is proud to be associated with CAALA (Consumer Attorneys Association of Los An...


CAOC - "Neural IT is proud to be associated with CAOC (Consumer Attorneys of California) as a Ven...


NYSTLA - "Neural IT is proud to be associated with NYSTLA (New York State Trial Lawyers Associati...

News & Events

MTMP Spring Conference - 2018
Neural IT Team got to pose with Mike Papantonio at the successful book signing event of ‘Law And
Neural IT Celebrates 14 Jubilant years of Accomplishments & Achievements!
Neural IT Celebrates 14 Jubilant years of Accomplishments & Achievements!
2nd Quarter 2018 Rewards & Recognition Program Celebrations
2nd Quarter 2018 ‘Rewards & Recognition Program’ Celebrations at NEURAL IT

Latest Tweets